We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.
Filters applied:

Search Results

Showing 1-20 of 730 results
  1. Dolutegravir-induced growth and lifespan effects in Caenorhabditis elegans

    Background

    Integrase strand transfer inhibitor (INSTIs)-based combination antiretroviral treatment in people living with HIV (PLWH) has been...

    Shin-Huei Kuo, Wen-Li Hsu, ... Tun-Chieh Chen in BMC Pharmacology and Toxicology
    Article Open access 07 December 2023
  2. Overexpression of Motopsin, an Extracellular Serine Protease Related to Intellectual Disability, Promotes Adult Neurogenesis and Neuronal Responsiveness in the Dentate Gyrus

    Motopsin, a serine protease encoded by PRSS12 , is secreted by neuronal cells into the synaptic clefts in an activity-dependent manner, where it...

    Shiori Miyata, Masayuki Tsuda, Shinichi Mitsui in Molecular Neurobiology
    Article 28 December 2023
  3. Physicochemical Characterization of Three Active Pharmaceutical Ingredients for Compound Glycyrrhizin Solid Formulation and Compatibility Analysis via Thermal and Non-thermal Techniques

    Purpose

    This study aimed to develop evaluation methods for multicomponent system interactions between drug excipients of three active pharmaceutical...

    **ang-yun **e, Zhan-ying Chang, ... **ao-li Gao in Journal of Pharmaceutical Innovation
    Article 23 May 2022
  4. Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment

    Dolutegravir (DTG) is a first-line antiretroviral drug (ARV) used in combination therapy for the treatment of human immunodeficiency virus type-1...

    Aditya N. Bade, JoEllyn M. McMillan, ... Howard E. Gendelman in Molecular Neurobiology
    Article Open access 14 August 2021
  5. Cocaine regulates antiretroviral therapy CNS access through pregnane-x receptor-mediated drug transporter and metabolizing enzyme modulation at the blood brain barrier

    Background

    Appropriate interactions between antiretroviral therapies (ART) and drug transporters and metabolizing enzymes at the blood brain barrier...

    Rodnie Colón Ortiz, Stephen Knerler, ... Dionna W. Williams in Fluids and Barriers of the CNS
    Article Open access 10 January 2024
  6. Enhanced Solubility and Bioavailability of Dolutegravir by Solid Dispersion Method: In Vitro and In Vivo Evaluation—a Potential Approach for HIV Therapy

    Being a candidate of BCS class II, dolutegravir (DTG), a recently approved antiretroviral drug, possesses solubility issues. The current research was...

    Sunita Chaudhary, Anroop B. Nair, ... Vimal Patel in AAPS PharmSciTech
    Article 09 April 2021
  7. New Antiretroviral Agents for HIV Infection

    The development of antiretroviral drugs for treatment of human immunodeficiency virus (HIV) infection is the most remarkable achievement in medical...
    Chapter 2023
  8. Applicability of Reddish-Orange Light Emitting Samarium (III) Complexes for Biomedical and Multifunctional Optoelectronic Devices

    Six crimson samarium (III) complexes based on β-ketone carboxylic acid and ancillary ligands were synthesized by adopting the grinding technique. All...

    Pooja Hooda, V. B. Taxak, ... Rajesh Kumar in Journal of Fluorescence
    Article 12 January 2022
  9. Combined cART including Tenofovir Disoproxil, Emtricitabine, and Dolutegravir has potent therapeutic effects in HIV-1 infected humanized mice

    HIV-1 reservoirs persist in the presence of combined antiretroviral therapy (cART). However, cART has transformed HIV-1 infection into a chronic...

    Matthew Weichseldorfer, Yvonne Affram, ... Olga S. Latinovic in Journal of Translational Medicine
    Article Open access 30 October 2021
  10. HIV drug resistance to integrase inhibitors in low- and middle-income countries

    Joseph Fokam, Seth Inzaule, ... Nicaise Ndembi in Nature Medicine
    Article 23 January 2024
  11. Tenofovir alafenamide plus dolutegravir as a switch strategy in HIV-infected patients: a pilot randomized controlled trial

    Background

    Currently, two-drug antiretroviral regimens are emerging fields in life-long treatment in people living with HIV.

    Objectives ...
    Golbarg Alavian, Ladan Abbasian, ... Seyed Ali Dehghan Manshadi in DARU Journal of Pharmaceutical Sciences
    Article 04 August 2023
  12. Role of Dysregulated Autophagy in HIV Tat, Cocaine, and cART Mediated NLRP3 Activation in Microglia

    Despite the ability of combination antiretroviral therapy (cART) to suppress viremia, there is persistence low levels of HIV proteins such as...

    Seema Singh, Annadurai Thangaraj, ... Shilpa Buch in Journal of Neuroimmune Pharmacology
    Article 06 May 2023
  13. Relationship between drug targets and drug-signature networks: a network-based genome-wide landscape

    Drugs produce pharmaceutical and adverse effects that arise from the complex relationship between drug targets and signatures; by considering such...

    Chae Won Lee, Sung Min Kim, ... Hyun Wook Han in BMC Medical Genomics
    Article Open access 30 January 2023
  14. Viral suppression rate at operation triple zero (Otz) and regular art follow-Up programs and associated factors among adolescent clients of Addis Ababa Ethiopia: a comparative cross-sectional study

    Background

    - Viral suppression is the main goal of currently available treatment and it is used as a primary indicator of successful treatment for...

    Getahun Wedaje Tafere, Fufa Hunduma, Aman Yesuf in Virology Journal
    Article Open access 08 September 2023
  15. A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection

    Integrase strand transfer inhibitors (INSTIs) have improved the treatment of human immunodeficiency virus (HIV). There are currently four approved...

    Alexa Vyain Zhao, Rustin D. Crutchley, ... Amy Cheng Min in Retrovirology
    Article Open access 22 October 2022
  16. Use of programmed cell death protein 1 (PD-1) inhibitor therapy in HIV-infected patients with advanced cancer: a single-center study from China

    Background

    Anti-PD-1 antibodies have been approved for treating several cancer. However, data regarding the safety and efficacy of these agents in...

    Luling Wu, Jie Su, ... Jun Chen in Infectious Agents and Cancer
    Article Open access 30 May 2023
  17. Learning from cerebrospinal fluid drug-resistant HIV escape-associated encephalitis: a case report

    Background

    In the era of antiretroviral therapy (ART), central nervous system (CNS) complications in patients with human immunodeficiency virus (HIV)...

    **g Kang, Ziqiu Wang, ... Ying Wen in Virology Journal
    Article Open access 10 December 2023
  18. Renal function and lipid metabolism in Japanese HIV-1-positive individuals 288 weeks after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate: a single-center, retrospective cohort study

    Background

    Continued use of tenofovir disoproxil fumarate (TDF), an antiretroviral drug, causes renal function decline and tubular damage in...

    Kensuke Abe, Junji Imamura, ... Toshihiro Ito in Journal of Pharmaceutical Health Care and Sciences
    Article Open access 28 February 2024
  19. FGF10 mitigates doxorubicin-induced myocardial toxicity in mice via activation of FGFR2b/PHLDA1/AKT axis

    Doxorubicin is a common chemotherapeutic agent in clinic, but myocardial toxicity limits its use. Fibroblast growth factor (FGF) 10, a...

    De-pu Zhou, Lian-cheng Deng, ... **-San Zhang in Acta Pharmacologica Sinica
    Article Open access 24 May 2023
Did you find what you were looking for? Share feedback.